[Federal Register Volume 74, Number 226 (Wednesday, November 25, 2009)]
[Rules and Regulations]
[Pages 61516-61517]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-28217]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, and 558

[Docket No. FDA-2009-N-0665]


New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect a change of sponsor for 29 new animal drug 
applications (NADAs) and 2 abbreviated new animal drug applications 
(ANADAs) from Intervet, Inc., to Schering-Plough Animal Health Corp.

DATES:  This rule is effective November 25, 2009.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for 
Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: Intervet, Inc., P.O. Box 318, 29160 Intervet 
Lane, Millsboro, DE 19966, has informed FDA that it has transferred 
ownership of, and all rights and interest in, the following 29 approved 
NADAs and 2 approved ANADAs to Schering-Plough Animal Health Corp., 556 
Morris Ave., Summit, NJ 07901: NADA 034-478, 034-621, 045-188, 102-380, 
104-494, 111-278, 120-648, 121-473, 128-620, 131-310, 131-675, 132-872, 
137-600, 138-612, 139-189, 140-856, 140-897, 140-927, 140-954, 140-992, 
141-222, 141-236, 141-258, 141-269, 141-276, 141-278, 141-280, 141-282, 
141-286; ANADA 200-134 and 200-239. Accordingly, the agency is amending 
the regulations in 21 CFR parts 520, 522 (21 CFR part 522), and 558 to 
reflect the transfer of ownership. In addition, Sec.  522.1081 is being 
revised to reflect a current format.
    Following these changes of sponsorship, Intervet, Inc., is no 
longer the sponsor of an approved application. Accordingly, 21 CFR 
510.600(c) is being amended to remove the entries for Intervet, Inc.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects

21 CFR Part 510

    Administrative practice and procedure, Animal drugs, Labeling, 
Reporting and recordkeeping requirements.

21 CFR Parts 520 and 522

    Animal drugs.

21 CFR Part 558

    Animal drugs, Animal feeds.

0
Therefore, under the Federal Food, Drug and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 
520, 522, and 558 are amended as follows:

PART 510--NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 510 continues to read as 
follows:

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.


Sec.  510.600  [Amended]

0
2. In Sec.  510.600, in the table in paragraph (c)(1), remove the entry 
for ``Intervet, Inc.''; and in the table in paragraph (c)(2), remove 
the entry for ``057926''.

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
3. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec.  520.48  [Amended]

0
4. In paragraph (b) of Sec.  520.48, remove ``057926'' and in its place 
add ``000061''.


Sec.  520.905a  [Amended]

0
5. In paragraph (b) of Sec.  520.905a, remove ``057926'' and in its 
place add ``000061''.


Sec.  520.905b  [Amended]

0
6. In paragraph (b) of Sec.  520.905b, remove ``057926'' and in its 
place add ``000061''.


Sec.  520.905c  [Amended]

0
7. In paragraph (b) of Sec.  520.905c, remove ``057926'' and in its 
place add ``000061''.


Sec.  520.905d  [Amended]

0
8. In paragraph (b)(1) of Sec.  520.905d, remove ``057926'' and in its 
place add ``000061''.


Sec.  520.905e  [Amended]

0
9. In paragraph (b) of Sec.  520.905e, remove ``057926'' and in its 
place add ``No. 000061''.


Sec.  520.1010  [Amended]

0
10. In paragraph (b)(2) of Sec.  520.1010, remove ``057926'' and in its 
place add ``000061''.


Sec.  520.1200  [Amended]

0
11. In paragraph (b) of Sec.  520.1200, remove ``057926'' and in its 
place add ``000061''.

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
12. The authority citation for 21 CFR part 522 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec.  522.246  [Amended]

0
13. In paragraph (b)(3) of Sec.  522.246, remove ``057926'' and in its 
place add ``000061''.


Sec.  522.1010  [Amended]

0
14. In paragraph (b)(4) of Sec.  522.1010, remove ``057926'' and in its 
place add ``000061''.


Sec.  522.1078  [Amended]

0
15. In paragraph (b) of Sec.  522.1078, remove ``Nos. 050604, 057926, 
and 059130'' and in its place add ``Nos. 000061, 050604, and 059130''.


Sec.  522.1079  [Amended]

0
16. In paragraph (b) of Sec.  522.1079, remove ``057926'' and in its 
place add ``000061''.

0
17. Revise Sec.  522.1081 to read as follows:


Sec.  522.1081  Chorionic gonadotropin.

    (a) Specifications. Each vial contains 5,000, 10,000 or 20,000 USP 
units of lyophilized powder for constitution with accompanying diluent 
to a 10-milliliter solution.

[[Page 61517]]

    (b) Sponsors. See sponsors in Sec.  510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) Nos. 000402 and 053501 for use as in paragraphs (d)(1)(i)(A), 
(d)(1)(i)(B) and (d)(1)(i)(C) of this section.
    (2) Nos. 058639 and 063323 for use as in paragraphs (d)(1)(i)(A) 
and (d)(1)(i)(B) of this section.
    (3) No. 000061 for use as in paragraphs (d)(1)(i)(A) and (d)(2) of 
this section.
    (c) Related tolerances. See Sec.  556.304 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. As a single dose. 
Dosage may be repeated in 14 days if the animal's behavior or 
examination of the ovaries per rectum indicates retreatment.
    (A) 10,000 USP units by intramuscular injection.
    (B) 500 to 2,500 USP units by intrafollicular injection.
    (C) 2,500 to 5,000 USP units by intravenous injection.
    (ii) Indications for use. For parenteral use in cows for treatment 
of nymphomania (frequent or constant heat) due to cystic ovaries.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Finfish--(i) Amount. 50 to 510 IU per pound of body weight for 
males, 67 to 1,816 IU per pound of body weight for females, by 
intramuscular injection. Up to three doses may be administered.
    (ii) Indications for use. An aid in improving spawning function in 
male and female brood finfish.
    (iii) Limitations. In fish intended for human consumption, the 
total dose administered per fish (all injections combined) should not 
exceed 25,000 IU chorionic gonadotropin. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.


Sec.  522.1160  [Amended]

0
18. In paragraph (b) of Sec.  522.1160, remove ``057926'' and in its 
place add ``000061''.


Sec.  522.2476  [Amended]

0
19. In paragraph (a)(2) of Sec.  522.2476, remove ``057926'' and in its 
place add ``000061''.


Sec.  522.2477  [Amended]

0
20. In paragraph (b)(2) of Sec.  522.2477, remove ``057926'' and in its 
place add ``000061''.

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
21. The authority citation for 21 CFR part 558 continues to read as 
follows:

    Authority: 21 U.S.C. 360b, 371.


Sec.  558.258  [Amended]

0
22. In paragraph (b) of Sec.  558.258, remove ``057926'' and in its 
place add ``000061''; and in the tables in paragraphs (e)(1) through 
(e)(5), in the ``Sponsor'' column, remove ``057926'' where it occurs 
and in its place add ``000061''.


Sec.  558.665  [Amended]

0
23. In paragraph (b) of Sec.  558.665, remove ``057926'' and in its 
place add ``000061''; and in the table in paragraph (e), in the 
``Sponsor'' column, remove ``057926'' where it occurs and in its place 
add ``000061''.

    Dated: November 19, 2009.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. E9-28217 Filed 11-24-09; 8:45 am]
BILLING CODE 4160-01-S